Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBR 900 in Healthy Volunteers
NCT02235727Phase 1Completed
- Sponsor
- Glenmark Pharmaceuticals
- Start
- Jul 2014
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic pain, osteoarthritis (OA) and neuropathic pain comparing GBR 900 with Placebo (2 arms). Primary endpoint: Drug related adverse events (AEs) or any serious AEs at 71 days. Started Jul 2014; status: completed.
02
Drugs
GBR-900
03
Conditions
chronic painosteoarthritis (OA)neuropathic pain
Beyond the preview
Go deeper on NCT02235727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02235727.